Sterile PBS or 0.9% saline for reconstitution/dilution. It is recommended to use the reconstituted/diluted product within one month.
Ipilimumab/伊匹木单抗 细胞实验
Cell Line
Concentration
Treated Time
Description
References
CHO cells
512 μg/ml
30 minutes
To evaluate the ability of Ipilimumab to block B7-CTLA-4 interaction, results showed Ipilimumab failed to effectively block
Cell Res. 2018 Apr;28(4):416-432
Monocyte-derived human macrophages
10 μg/mL
overnight
Assess ADCC activity of anti-CTLA-4 antibodies in the presence of effector cells
Cancer Cell. 2018 Apr 9;33(4):649-663. e4
SupT1-mCTLA-4 cells
10 μg/mL
overnight
Evaluate ADCC activity of different human antibody isotypes or Fc-engineered variants against CTLA-4 expressing cells
Cancer Cell. 2018 Apr 9;33(4):649-663. e4
HEK293T cells
10 μg/ml
2 hours
To evaluate the ability of Ipilimumab to block B7-CTLA-4 mediated cell-cell interaction, results showed poor efficacy
Cell Res. 2018 Apr;28(4):416-432
Ipilimumab/伊匹木单抗 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Mice
Ctla4h/h mice
Intraperitoneal injection
100 μg/mouse
Single injection, lasting 4 hours
To evaluate the effect of Ipilimumab on CTLA-4 levels in mouse Tregs, results showed that Ipilimumab significantly downregulated both cell surface and total CTLA-4 levels in Tregs from lung and spleen.
Cell Res. 2019 Aug;29(8):609-627
Mice
C57BL/6N mice
Intravenous
10 mg/kg
Twice per week for a total of four doses
To evaluate the efficacy of anti-CTLA-4 treatment in four melanoma models. Results showed that M1 and M2 models were resistant to treatment, while M3 and M4 models were partially or highly sensitive.
Nat Med. 2020 May;26(5):781-791
C57BL/6 mice
B16/BL6 melanoma model
Intraperitoneal injection
200 μg (day 3) and 100 μg (day 6 and 9)
Administered on days 3, 6, and 9
To evaluate the effect of IFNGR1 knockdown on anti-CTLA-4 therapy. Results showed that IFNGR1 knockdown tumors had impaired response to anti-CTLA-4 therapy, with faster tumor growth and significantly reduced mouse survival.
Cell. 2016 Oct 6;167(2):397-404. e9
Mice
Human CTLA4 gene knock-in mice
Intraperitoneal injection
500 μg/mouse
Spleen cells collected 24 hours after a single injection
To evaluate the ability of Ipilimumab to block B7-CTLA-4 interaction in vivo, results showed Ipilimumab failed to upregulate B7-1 and B7-2 expression
搜索
